AUTHOR=Watanabe Motoko , Takao Chihiro , Liu Zhenyan , Nayanar Gayatri , Suga Takayuki , Hong Chaoli , Tu Trang Thi Huyen , Yoshikawa Tatsuya , Takenoshita Miho , Motomura Haruhiko , Nagamine Takahiko , Toyofuku Akira 

TITLE=The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS

JOURNAL=Frontiers in Pain Research

VOLUME=Volume 3 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2022.809207

DOI=10.3389/fpain.2022.809207

ISSN=2673-561X

ABSTRACT=Burning mouth syndrome (BMS) is defined by chronic oral burning sensations without any corresponding abnormalities. Besides amitriptyline, aripiprazole has been reported as a possible medication to manage BMS. However, especially for the elderly patients, the adverse events of these medications would be a problem. The aim of the present study was to investigate the differences of the effectiveness and adverse events of amitriptyline and aripiprazole in very elderly patients with BMS. This is a retrospective comparative study of 80 years old and older BMS patients who were initially treated with amitriptyline or aripiprazole and who were new outpatients of our department from April 2017 to March 2020. All clinical data, including sex, age, comorbid physical diseases, comorbid psychiatric disorders, the prescribed doses (initial, maximum and effective dose), prognosis and adverse events were collected from their medical charts. Each medication was selected considering their medical history. Amitriptyline was prescribed in 13 patients (11 females, 82.3 ± 2.1 years old) and aripiprazole was prescribed in 27 patients (26 females, 84.2 ± 3.8 years old). There was no significant between-group difference in sex, age, duration of illness, pain intensity, salivation and psychiatric comorbidity at the first examination. Amitriptyline clinically improved more patients (7 patients, 53.8%) with the effective dose 10 (7.5, 15.0) mg than aripiprazole (11 patients, 40.7%) of which the effective dose was 1.0 (0.5, 1.5) mg although there was no significant between-group difference. The adverse events of amitriptyline were found in 9 patients (69.2%) and most was constipation (46.2%). For aripiprazole, 7 patients (25.9%) showed adverse events mostly sleep disorder (11.1%). Amitriptyline had significantly longer duration taking medication (p = 0.021) and lower discontinuation (p = 0.043) despite of higher occurrence rate of adverse events (p = 0.015) compared to aripiprazole. These results suggest that both psychopharmacotherapies with low dose of amitriptyline and aripiprazole are effective for the very elderly BMS patients. Furthermore, aripiprazole may have some advantages in the adverse events compared to amitriptyline; however, the low dose amitriptyline monotherapy may have more benefit in the effectiveness and tolerability over prudent collaboration with primary physicians.